Prostatype Genomics AB Cash Flow-to-Debt Ratio
Prostatype Genomics AB cash flow-to-debt ratio. Prostatype Genomics AB (PROGEN) has a Cash Flow-to-Debt Ratio of -1.16x as of June 2025, meaning its operating cash flow of Skr-8.54 Million could theoretically repay -1% of its total liabilities (Skr7.36 Million) in one year. See Prostatype Genomics AB free cash flow to debt ratio to measure the company's free cash flow as a share of total liabilities.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Cash Flow-to-Debt Ratio of Prostatype Genomics AB (2016–2024)
Cash flow-to-debt ratio of Prostatype Genomics AB from 2016 to 2024. Historical debt coverage capacity for Prostatype Genomics AB across 8 annual periods. Check total reinvestment intensity of Prostatype Genomics AB to assess the company's total reinvestment commitment from operating cash flow.
Prostatype Genomics AB Cash Flow-to-Debt Ratio by Year (2016–2024)
Prostatype Genomics AB cash flow-to-debt ratio by year from 2016 to 2024. Year-by-year debt coverage analysis for Prostatype Genomics AB. For the full cash flow conversion analysis, see Prostatype Genomics AB (PROGEN) cash flow conversion.
| Year | CF-to-Debt Ratio | Operating CF (SEK) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2024 | -5.26x | Skr-44.71 Million | Skr8.50 Million | ▼ -343.1% |
| 2023 | -1.19x | Skr-29.14 Million | Skr24.55 Million | ▲ +79.4% |
| 2022 | -5.77x | Skr-27.69 Million | Skr4.80 Million | ▼ -54.2% |
| 2021 | -3.74x | Skr-16.08 Million | Skr4.30 Million | ▼ -36.6% |
| 2020 | -2.74x | Skr-14.71 Million | Skr5.37 Million | ▼ -156.7% |
| 2018 | -1.07x | Skr-9.63 Million | Skr9.03 Million | ▼ -152.0% |
| 2017 | -0.42x | Skr-5.71 Million | Skr13.49 Million | ▲ +79.0% |
| 2016 | -2.01x | Skr-9.63 Million | Skr4.79 Million | — |